These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19225094)

  • 1. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.
    Navab M; Ruchala P; Waring AJ; Lehrer RI; Hama S; Hough G; Palgunachari MN; Anantharamaiah GM; Fogelman AM
    J Lipid Res; 2009 Aug; 50(8):1538-47. PubMed ID: 19225094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.
    Nayyar G; Garber DW; Palgunachari MN; Monroe CE; Keenum TD; Handattu SP; Mishra VK; Anantharamaiah GM
    Atherosclerosis; 2012 Oct; 224(2):326-31. PubMed ID: 22771190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.
    Woo JM; Lin Z; Navab M; Van Dyck C; Trejo-Lopez Y; Woo KM; Li H; Castellani LW; Wang X; Iikuni N; Rullo OJ; Wu H; La Cava A; Fogelman AM; Lusis AJ; Tsao BP
    Arthritis Res Ther; 2010; 12(3):R93. PubMed ID: 20482780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Hama S; Hough G; Reddy ST; Frank JS; Garber DW; Handattu S; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1426-32. PubMed ID: 15845909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation.
    Buga GM; Navab M; Imaizumi S; Reddy ST; Yekta B; Hough G; Chanslor S; Anantharamaiah GM; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):283-9. PubMed ID: 19965777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of L-4F and simvastatin stimulate cholesterol efflux and related proteins expressions to reduce atherosclerotic lesions in apoE knockout mice.
    Ying R; Yuan Y; Qin YF; Tian D; Feng L; Guo ZG; Sun YX; Li MX
    Lipids Health Dis; 2013 Dec; 12():180. PubMed ID: 24314261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.
    Navab M; Anantharamaiah GM; Hama S; Garber DW; Chaddha M; Hough G; Lallone R; Fogelman AM
    Circulation; 2002 Jan; 105(3):290-2. PubMed ID: 11804981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.
    Qin S; Kamanna VS; Lai JH; Liu T; Ganji SH; Zhang L; Bachovchin WW; Kashyap ML
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):334-43. PubMed ID: 22308547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease.
    Handattu SP; Garber DW; Monroe CE; van Groen T; Kadish I; Nayyar G; Cao D; Palgunachari MN; Li L; Anantharamaiah GM
    Neurobiol Dis; 2009 Jun; 34(3):525-34. PubMed ID: 19344763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential clinical utility of high-density lipoprotein-mimetic peptides.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
    Curr Opin Lipidol; 2006 Aug; 17(4):440-4. PubMed ID: 16832169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.
    Navab M; Reddy ST; Anantharamaiah GM; Imaizumi S; Hough G; Hama S; Fogelman AM
    J Lipid Res; 2011 Jun; 52(6):1200-1210. PubMed ID: 21444758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.
    Meriwether D; Imaizumi S; Grijalva V; Hough G; Vakili L; Anantharamaiah GM; Farias-Eisner R; Navab M; Fogelman AM; Reddy ST; Shechter I
    J Lipid Res; 2011 Oct; 52(10):1795-809. PubMed ID: 21804067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes.
    Morgantini C; Imaizumi S; Grijalva V; Navab M; Fogelman AM; Reddy ST
    Diabetes; 2010 Dec; 59(12):3223-8. PubMed ID: 20826564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity.
    Madenspacher JH; Azzam KM; Gong W; Gowdy KM; Vitek MP; Laskowitz DT; Remaley AT; Wang JM; Fessler MB
    J Biol Chem; 2012 Dec; 287(52):43730-40. PubMed ID: 23118226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.
    Wool GD; Cabana VG; Lukens J; Shaw PX; Binder CJ; Witztum JL; Reardon CA; Getz GS
    FASEB J; 2011 Jan; 25(1):290-300. PubMed ID: 20876212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice.
    Handattu SP; Datta G; Epand RM; Epand RF; Palgunachari MN; Mishra VK; Monroe CE; Keenum TD; Chaddha M; Anantharamaiah GM; Garber DW
    J Lipid Res; 2010 Dec; 51(12):3491-9. PubMed ID: 20841495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis.
    Charles-Schoeman C; Banquerigo ML; Hama S; Navab M; Park GS; Van Lenten BJ; Wagner AC; Fogelman AM; Brahn E
    Clin Immunol; 2008 May; 127(2):234-44. PubMed ID: 18337176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.